Granules India (532482) Aktienübersicht
Granules India Limited produziert und verkauft pharmazeutische Wirkstoffe (APIs), pharmazeutische Zwischenprodukte und Fertigarzneimittel (FDs) in Indien und international. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 1/6 |
| Künftiges Wachstum | 4/6 |
| Vergangene Leistung | 5/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 4/6 |
Belohnungen
Risikoanalyse
Bei unseren Risikoprüfungen wurden keine Risiken für 532482 festgestellt.
532482 Community Fair Values
Create NarrativeSee what 24 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Granules India Limited Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | ₹841.70 |
| 52-Wochen-Hoch | ₹910.00 |
| 52-Wochen-Tief | ₹455.00 |
| Beta | 0.14 |
| 1 Monat Veränderung | -3.86% |
| 3 Monate Veränderung | 11.99% |
| 1 Jahr Veränderung | 82.30% |
| 3 Jahre Veränderung | 185.52% |
| 5 Jahre Veränderung | 157.99% |
| Veränderung seit IPO | 27,496.72% |
Aktuelle Nachrichten und Updates
Narrative-Update • Aug 05
532482: Fair Outlook Will Hinge On Q1 2026 Results And Sole FTF ANDAs
Analysts have raised their price target for Granules India from about ₹786 to roughly ₹919, citing model updates that reflect unchanged discount rates, along with revised assumptions for revenue growth, profit margins and future P/E levels. What's in the News for Granules India Granules India has scheduled a board meeting on July 21, 2026, to consider and approve the unaudited financial results for the first quarter that ended on June 30, 2026.
Narrative-Update • Jul 22
532482: Sole FTF Complex Generics Will Drive Future Margins And Fair Value
Analysts have raised their price target for Granules India from ₹931 to ₹1,110, reflecting updated assumptions for revenue growth, profit margins and future P/E expectations. What’s in the News for Granules India Granules India has scheduled a board meeting on July 21, 2026 to consider and approve its unaudited financial results for the first quarter ended June 30, 2026.Recent updates
Narrative-Update • Aug 05
532482: Fair Outlook Will Hinge On Q1 2026 Results And Sole FTF ANDAs
Analysts have raised their price target for Granules India from about ₹786 to roughly ₹919, citing model updates that reflect unchanged discount rates, along with revised assumptions for revenue growth, profit margins and future P/E levels. What's in the News for Granules India Granules India has scheduled a board meeting on July 21, 2026, to consider and approve the unaudited financial results for the first quarter that ended on June 30, 2026.Narrative-Update • Jul 22
532482: Sole FTF Complex Generics Will Drive Future Margins And Fair Value
Analysts have raised their price target for Granules India from ₹931 to ₹1,110, reflecting updated assumptions for revenue growth, profit margins and future P/E expectations. What’s in the News for Granules India Granules India has scheduled a board meeting on July 21, 2026 to consider and approve its unaudited financial results for the first quarter ended June 30, 2026.Narrative-Update • Jul 08
532482: Future Margins And Dividend Policy Will Shape Fair Value
The analyst fair value estimate for Granules India has been revised from ₹856 to ₹931, with analysts pointing to updated assumptions related to slightly higher revenue growth, profit margins and future P/E expectations. What's in the News Granules India board meeting is scheduled for April 29, 2026, to consider and approve audited financial results for the fourth quarter and full year ended March 31, 2026, and to discuss a potential final dividend for FY 2025-26.Narrative-Update • Jun 11
532482: Fair Outlook Will Hinge On Upcoming FY 2025-26 Results And Dividend
Analysts have nudged their price target for Granules India higher to about ₹786 from roughly ₹698, citing updated assumptions that reflect adjusted revenue growth, profit margin expectations, discount rate inputs, and a revised future P/E multiple. What's in the News A board meeting is scheduled for April 29, 2026, to consider and approve audited financial results for the fourth quarter and full year ended March 31, 2026, and to consider a final dividend for FY 2025-26, if any.Narrative-Update • May 28
532482: Fair Value Will Depend On Margins And Dividend Sustainability
Analysts have lifted their price target on Granules India from ₹799 to ₹856, reflecting updated assumptions on the discount rate, revenue growth, profit margins, and future P/E expectations. What's in the News The board meeting is scheduled for April 29, 2026 to consider and approve audited financial results for Q4 and the full year ended March 31, 2026, and to consider a final dividend for FY 2025-26, if any (Key Developments).Narrative-Update • May 01
532482: Fair Outlook Will Depend On Upcoming Results And Dividend Decision
Analysts have nudged their price target for Granules India up from about ₹678 to about ₹698, citing updated assumptions that reflect slightly higher projected revenue growth, profit margins, and a modestly adjusted future P/E multiple. What's in the News Board meeting scheduled for April 29, 2026 to consider and approve audited financial results for Q4 and the full year ended March 31, 2026, along with a potential final dividend recommendation for FY 2025-26 (company announcement).Narrative-Update • Apr 17
532482: Fair Outlook Will Rely On Upcoming Results And Capital Deployment
Analysts have lifted their fair value estimate for Granules India from about ₹647 to roughly ₹678, citing updated assumptions around long term revenue growth, profit margins and future P/E expectations. What's in the News Board meeting scheduled for April 29, 2026 to consider and approve audited financial results for the fourth quarter and full year ended March 31, 2026, and to consider a final dividend for FY 2025-26, if any (Key Developments).Narrative-Update • Apr 03
532482: Higher Fair Value Will Rely On Sustained Margin Improvement
Analysts have raised their price target on Granules India from ₹700.00 to about ₹799.28, reflecting updated views on fair value, discount rate assumptions, revenue growth and profit margin expectations, along with a lower future P/E multiple. What's in the News Granules India closed a private placement transaction on February 23, 2026, indicating recent activity in its capital raising plans (Key Developments).Narrative-Update • Mar 20
532482: Capital Raise Through Convertible Warrants Will Support Future Earnings Upside Potential
Analysts have inched up their price target on Granules India from about ₹641 to around ₹647, reflecting updated assumptions that combine a slightly lower discount rate with higher projected revenue growth, improved profit margins and a more modest future P/E multiple. What's in the News The board of directors approved plans to raise a total of INR 17,625.0 million through a mix of convertible warrants and fresh equity, including up to 25.0 million convertible warrants at INR 585 each and up to 5,128,000 fully paid equity shares at INR 585 per share to selected non promoter investors (Key Developments).
Narrative-Update • Mar 05
532482: Preferential Fundraising And Warrants Will Shape A Steady Outlook
Analysts have kept their fair value estimate for Granules India steady at ₹588. They have fine tuned their underlying assumptions around revenue growth, profit margins and future P/E to reflect updated expectations, without changing the overall price target.Narrative-Update • Feb 19
532482: Fundraising Plans And Research Centres Will Shape A Balanced Outlook
Analysts have kept their fair value estimate for Granules India steady at ₹588, with only minor model tweaks to revenue growth, profit margin and future P/E assumptions informing this unchanged price target. What's in the News Board meeting scheduled on January 23, 2026 to consider and approve unaudited financial results for the third quarter and nine months ended December 31, 2025 (company filing).Narrative-Update • Feb 05
532482: Future Fundraising And R&D Initiatives Will Shape A Fair Outlook
Analysts have lifted their fair value estimate for Granules India from ₹480.00 to ₹588.00, citing slightly adjusted assumptions on the discount rate, revenue growth, profit margins and future P/E ratio to support the higher price target. What's in the News The board has approved proposals to raise a total of ₹17,625.0m through preferential issuance of convertible warrants and equity shares.Narrative-Update • Jan 22
532482: Fundraising Through Convertible Warrants Will Support Earnings Upside Potential
Analysts have maintained their fair value estimate for Granules India at ₹640.71 per share, citing unchanged assumptions for discount rate, revenue growth, profit margin and future P/E that reflect a consistent view of the company’s long-term earnings potential. What's in the News A board meeting is scheduled on January 23, 2026 to consider and approve unaudited financial results for the third quarter and nine months ended December 31, 2025.Narrative-Update • Jan 07
532482: Fundraising Plans And US Compliance Outlook Will Shape Balanced Future
Analysts have nudged up their fair value estimate for Granules India from ₹632.14 to ₹640.71 per share, reflecting refreshed assumptions on long term revenue growth, profit margin stability, and a slightly higher future P/E multiple in their models. What's in the News The board has approved plans to raise a total of ₹17,625.0 million via a preferential issuance of up to 2.5 crore convertible warrants and additional equity shares at ₹585 each.Narrative-Update • Dec 14
532482: Upcoming German Acquisition And US Compliance Will Shape Balanced Outlook
Analysts have modestly reaffirmed their stance on Granules India, keeping the fair value estimate steady at ₹632.14 per share. They continue to forecast solid mid teens revenue growth and stable profit margins, supported by consistent execution and unchanged valuation multiples.Narrative-Update • Nov 28
532482: Upcoming Board Decision On German Acquisition Will Drive Future Performance
Analysts have increased their price target for Granules India from ₹604.29 to ₹632.14, citing improved revenue growth forecasts. These forecasts are considered significant enough to offset a slight reduction in projected profit margins.Narrative-Update • Nov 14
532482: Upcoming Regulatory Milestone And Profitability Outlook Will Shape Performance
Analysts have raised their price target for Granules India from ₹573.71 to ₹604.29. They cited improved profitability forecasts, even though revenue growth expectations are slightly lower.Narrative-Update • Aug 27
FDA Remediation And Genome Valley Ramp-Up Will Unlock Capacity
The slight downward revision in Granules India’s consensus price target to ₹573.71 reflects marginally lower future P/E and revenue growth forecasts. What's in the News Dr. Kandiraju Venkata Sitaram Rao will resign as CEO of Granules India, effective at the close of business on July 31, 2025.
Neues Narrative • Feb 17
New Genome Valley Facility Will Increase Production Capacity To 10 Billion Doses
Strategic focus on expanding high-growth segments is expected to drive future revenue and enhance earnings stability through improved product approvals.Aktionärsrenditen
| 532482 | IN Pharmaceuticals | IN Markt | |
|---|---|---|---|
| 7D | -1.8% | -1.0% | -1.0% |
| 1Y | 82.3% | 15.7% | 1.2% |
Rendite im Vergleich zur Industrie: 532482 übertraf die Branche Indian Pharmaceuticals , die im vergangenen Jahr eine Rendite von 15.7 erzielte.
Rendite vs. Markt: 532482 übertraf den Markt Indian, der im vergangenen Jahr eine Rendite von 1.2 erzielte.
Preisvolatilität
| 532482 volatility | |
|---|---|
| 532482 Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.6% |
Stabiler Aktienkurs: 532482 hatte in den letzten 3 Monaten im Vergleich zum Indian -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: 532482Die wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1984 | 4,306 | Krishna Chigurupati | www.granulesindia.com |
Granules India Limited produziert und verkauft pharmazeutische Wirkstoffe (APIs), pharmazeutische Zwischenprodukte und Fertigarzneimittel (FDs) in Indien und auf internationaler Ebene. Zu den APIs des Unternehmens in verschiedenen therapeutischen Kategorien gehören antiretrovirale Mittel, Antihypertonika, Antihistaminika, Antiinfektiva, Analgetika, Antikoagulanzien, Antifibriotika und Thrombozytenhemmer. Darüber hinaus bietet das Unternehmen Tabletten, Kapseln und Pressfit-Kapseln als Bulkware, in Blisterpackungen und Flaschen, hochwirksame Produkte und andere Produkte für die Onkologie an.
Granules India Limited's Grundlagenzusammenfassung
| 532482 grundlegende Statistiken | |
|---|---|
| Marktanteil | ₹208.57b |
| Gewinn(TTM) | ₹6.62b |
| Umsatz(TTM) | ₹56.32b |
31.5x
Kurs-Gewinn-Verhältnis 3.7x
Kurs-Umsatz-VerhältnisIst 532482 zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| 532482 Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | ₹56.32b |
| Kosten der Einnahmen | ₹21.40b |
| Bruttogewinn | ₹34.92b |
| Sonstige Ausgaben | ₹28.30b |
| Gewinn | ₹6.62b |
Zuletzt gemeldete Gewinne
Jun 30, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 26.73 |
| Bruttomarge | 62.00% |
| Nettogewinnspanne | 11.76% |
| Schulden/Eigenkapital-Verhältnis | 29.7% |
Wie hat sich 532482 auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
0.2%
Aktuelle Dividendenrendite7%
AusschüttungsquoteZahlt 532482 eine zuverlässige Dividende?
Siehe 532482 Dividendenhistorie und Benchmarks| Granules India Dividendentermine | |
|---|---|
| Ex-Dividenden Datum | Jul 30 2026 |
| Datum der Dividendenzahlung | Sep 05 2026 |
| Tage bis Ex-Dividende | 22 days |
| Tage bis zum Datum der Dividendenzahlung | 15 days |
Zahlt 532482 eine zuverlässige Dividende?
Siehe 532482 Dividendenhistorie und BenchmarksUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/20 23:19 |
| Aktienkurs zum Tagesende | 2026/08/20 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Granules India Limited wird von 13 Analysten beobachtet. 7 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Vijayaraghavan Swaminathan | Avendus Spark |
| Harith Ahamed | Avendus Spark |
| Cyndrella Carvalho | Centrum Broking Limited |